Figure 1

Timecourse of disease progression and effectiveness of tolerisation on clinical relapses, disease progression and IgG immunoreactivity. Timeline illustrating experimental groupings following EAE induction (29, 58 and 105 days) and timepoints when tolerisation was instigated and collection of tissue occurred (a). Behavioural data (b) showing disease progression of EAE in Biozzi ABH mice (black line) compared to early (red, tolerised day 29) and late (green, tolerised day 58) tolerised mice, where 0 is normal upto 5, moribund. Representative IgG images from the cervical spinal (c) cord showing normal (N = 3) compared to EAE disease progression at day 29 (N = 5), 58 (N = 5), 105 (N = 4), early (N = 4) and late tolerisation (N = 6). Quantification of IgG immunoreactivity (d) showing there are clear, significant increases in intensity (over the first 200 μm from the surface of the dorsal funiculus down) At day 29, 58 and 105 (black asterisk, d). Following early and late tolerisation there is a significant reduction compared to day 105-crEAE (red and green lines/asterisk respectively d, asterisk = P < 0.01, one-way ANOVA). Scale bar = 200 μm for all images.